ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity.
about
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Human apolipoprotein A-I-derived amyloid: its association with atherosclerosisTransthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor.Substrate specificity of transthyretin: identification of natural substrates in the nervous system.Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients.Sampling the N-terminal proteome of human blood.Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families.Tamarindus indica extract alters release of alpha enolase, apolipoprotein A-I, transthyretin and Rab GDP dissociation inhibitor beta from HepG2 cellsTransthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice.Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state.Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.Evolutionary changes to transthyretin: structure-function relationships.The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils.Interaction between the N- and C-terminal domains modulates the stability and lipid binding of apolipoprotein A-I.Amyloid substance within stenotic aortic valves promotes mineralization.Mechanisms of action of Coxiella burnetii effectors inferred from host-pathogen protein interactions.Novel mutations in transthyretin gene associated with hepatocellular carcinoma.Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation.Transthyretin is a metallopeptidase with an inducible active siteTransthyretin in peripheral nerve regeneration
P2860
Q21202832-34A2B636-7DB2-4CD6-829D-7FC967F4335FQ28479210-BAF79567-2161-4614-A33C-8786D7AC1178Q33358106-60B85C5F-A1CC-48C0-B244-1BBDC97629EBQ33399237-E7D3F80E-FEAD-4C12-A03F-8FEAFD064F0CQ33497345-17E7A216-E8CE-4023-92E3-68688E7EDD1BQ33740667-28D227E4-6F3E-4AF5-9374-3AAB4E4EDC23Q34091682-B08CA0C1-F1F0-4A39-822F-AA5068642B81Q34314466-6D12FB5D-0E8A-44FD-993E-C0C0EBEB1187Q35532291-6D5206BB-89E8-46C2-A95D-1F50E5354B02Q37460991-AAC11E38-8DB0-4B06-A70D-8D3D8D69FDA7Q37528535-60E24592-EE00-4C8B-B83D-B6238021FBA1Q37590890-7995B496-029C-4E18-86A8-AC0910BDA89AQ40989004-4ECE37D8-A5A9-43F4-B84E-513A58B500BFQ42173718-2A6781E5-B7BE-420B-BF1C-EDEA241BFDA5Q46939306-DCD25650-DF92-474E-8630-9A6DFD3AD305Q47138796-1EA09D8C-D60F-41E3-94E1-6C281EA3C1EFQ47849340-40E28D0E-917A-4525-80FD-DB8F8FC86B82Q51725959-B37E450F-6126-4BFB-A545-1183FB0FD041Q58154013-A5A1CDC6-0636-4685-9D65-10AEFF3EE8BCQ58154103-4259D735-97F4-4CB5-8A69-2EF6E416B4C9
P2860
ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@en
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@nl
type
label
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@en
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@nl
prefLabel
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@en
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@nl
P2860
P50
P1476
ApoA-I cleaved by transthyreti ...... nd increased amyloidogenicity.
@en
P2860
P304
P356
10.1194/JLR.M700158-JLR200
P577
2007-08-10T00:00:00Z